UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/559,115	06/08/2006	Indu Mani	J2071(C)	1305
UNILEVER PATENT GROUP 800 SYLVAN AVENUE			EXAMINER	
			DAVIS, DEBORAH A	
AG West S. Wing ENGLEWOOD CLIFFS, NJ 07632-3100		00	ART UNIT	PAPER NUMBER
			1655	
			MAIL DATE	DELIVERY MODE
			03/27/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/559,115	MANI ET AL.			
Office Action Summary	Examiner	Art Unit			
	DEBORAH A. DAVIS	1655			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w.  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 14 Au     This action is <b>FINAL</b> . 2b) ☑ This     Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-8 is/are pending in the application.  4a) Of the above claim(s) is/are withdrav  5) ☐ Claim(s) is/are allowed.  6) ☐ Claim(s) 1-8 is/are rejected.  7) ☐ Claim(s) is/are objected to.  8) ☐ Claim(s) are subject to restriction and/or  Application Papers  9) ☐ The specification is objected to by the Examine 10) ☐ The drawing(s) filed on is/are: a) ☐ accession.	r election requirement.	Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 12-2-05.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

## **DETAILED ACTION**

Claims 1-8 are under consideration for examination on the merits.

## Claim Rejections - 35 USC § 112

Claim 6 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The limitation "wherein the skin whitening agent is niacin, niacinamide or a precursor thereof" is vague because it is unclear as to what the precursor of these agents are.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Osumi et al Japanese publication (JP20033055184) in view of Deckner et al (US 5,968,528).

The claims are drawn to a skin lightening composition, comprising 0.1-50% by weight of extracts of plants from the genera Symplocos and Rubia; the extract of Symplocos being selected from Symplocos recemosa, Symplocos paniculata,

Symplocos cochinchinesis or mixtures thereof; the extract of Rubia being Rubia cordifolia.

The reference of Osumi et al beneficially teaches a skin care composition with bleaching (i.e. whitenting) action comprising an extract from the plant Symplocos racemosa. The extracts from Symplocos can be extracted from the bark or other parts of the plant. The extracts from Symplocos have excellent active oxygen scavenging activity, collagenase inhibitory and tyrosinase inhibitory actions. The skin care composition has excellent aging preventing actions and good stability (see abstract, and pages 1-3, e.g.).

The reference of Deckner et al. beneficially teaches a skin care composition to treat the signs of aging. The composition comprising vitamin B3, especially niacinamide and can also comprise of other dermatological active ingredients such as extracts from the plants of the genus Rubia, particularly Rubia Cordifolia, sunscreen agents such as 2-ethyl hexyl methoxycinnamate, skin lightening agents, and glycyrrhiza (licorice) (columns 28, lines 14-44; 29, lines 57-6; 31, lines 41-60, e.g.).

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the instant ingredients for their known benefit since each is well known in the art for the same purpose (e.g., in skin compositions for skin conditioning) and for the following reasons. It is well known that it is prima facie obvious to combine two or more ingredients each of which is taught by the prior art to be useful for the same purpose in order to form a third composition which is useful for the same purpose. The idea for combining them flows logically from their having been used

individually in the prior art. In re Kerkhoven, 626 F.2d 846, 850, 205 U.S.P.Q. 1069 (CCPA 1980), In re Sussman, 1943 C.D. 518; In re Pinten, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); In re Susi, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); In re Crockett, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients. With respect to the percent by weight of the claimed ingredients in the instant composition is viewed as judicious selection and adjustments of particular working conditions that are within the purview of one skilled in the art.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

## Conclusion

No claim is allowed.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Application/Control Number: 10/559,115

Art Unit: 1655

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBORAH A. DAVIS whose telephone number is (571)272-0818. The examiner can normally be reached on 8-5 Monday thru Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571) 272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Deborah A. Davis Patent Examiner, AU 1655 February 2009 /Christopher R. Tate/ Primary Examiner, Art Unit 1655

Page 5